menu
    • menu
    [{"orgOrder":0,"company":"AcuCort","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"AcuCort","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"AcuCort \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"AcuCort \/ Kamada"}]

    Find Clinical Drug Pipeline Developments & Deals by AcuCort

    Menu

    AcuCort

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    AcuCort

    Sweden arrow
    Interphex
    Not Confirmed

    AcuCort

    Sweden arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dexamethasone

    Therapeutic Area : Immunology

    Study Phase : Approved FDF

    Sponsor : Kamada

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    AcuCort Signs Its First Commercial Agreement for The Company's Drug Zeqmelit™

    Details : Under the terms of the agreement, Kamada is responsible for the commercialization of Zeqmelit™ (dexamethasone) in Israel and has the exclusive right to marketing, sales, and distribution of the drug in this market.

    Product Name : Zeqmelit

    Product Type : Steroid

    Upfront Cash : Undisclosed

    November 23, 2022

    Lead Product(s) : Dexamethasone

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Sponsor : Kamada

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth